key: cord-0812905-t6um24tl
authors: Caceres, Jennifer; Maki, Dennis G.; Hennekens, Charles H.
title: Cautious Optimism and Considerations for Health Providers and Patients: Oral antiviral for early treatment of high risk patients and vaccines for prevention of COVID-19
date: 2022-03-17
journal: Am J Med
DOI: 10.1016/j.amjmed.2022.02.041
sha: 72392294be65d3b3181561ba4cace6b5b3fc4185
doc_id: 812905
cord_uid: t6um24tl

nan

On December 22, 2021, the United States (US) Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for the first oral antiviral, a pill containing two protease inhibitors, nirmatrelvir and ritonavir (Paxlovid, Pfizer), for the early treatment of COVID-19. (1) This drug was approved for adults 18 years of age and older with acute COVID-19 as well as having a pre-specified risk factor for progression to severe disease or 60 years of age or older regardless of chronic medical conditions. The pivotal trial enrolled high-risk newly-infected patients who had neither received a COVID-19 vaccine nor had been previously infected. The pre-specified primary outcome was hospitalization due to COVID-19 or death from any cause during 28 days of follow-up. Among 2085 randomized subjects, the primary outcome occurred in 0.8% of 1039 who received the active drug (1 death) and 7.8% of 1046 given placebo (10 deaths), a highly significant 88% reduction. (1) The following day, the FDA issued another EUA for a novel viral RNA polymerase inhibitor, molnupiravir (Merck/Ridgeback Biotherapeutics). Last month advisers to the FDA debated about benefits and risks. First, the benefit is far lower than for nirmatrelvir and ritonavir and second, risks include the possibility of mutations that might make the virus more dangerous or transmissible. (2) In a randomized trial in 1408 randomized subjects, the primary outcome occurred in 6.8% among 709 assigned to molnupriavir and 9.7% of 699 given a placebo, a significant but much lower 30% reduction. The advisory committee was split on molnupriavir, with a 13-10 vote approving the drug. (3) In this Commentary, we express optimism to health providers regarding the potentially large clinical and public health impacts of their judicious prescription of the new oral antiviral drugs to prevent progression of early COVID-19 in high-risk patients, as well as their wider use of vaccines to prevent severe and fatal COVID-19 infections.

With respect to early preemptive antiviral therapy, the new oral antiviral drugs are projected to cost approximately $500 and can be taken at home. (1, 3) To preserve antiviral efficacy for as long as possible, these drugs must be prescribed judiciously by health care providers. This implies that the oral antiviral drug should be prescribed to patients with symptoms of COVID-19 of 5 days or less as well as proof of a positive standardized diagnostic test. These drugs should not be prescribed for either worried uninfected patients or immunized infected patients at low risk of progression to severe disease. Health care providers should be aware that their unrestricted widespread prescription and prolonged use will likely accelerate the emergence and rapid spread of variants highly resistant to these promising drugs, as occurred with amantadine and rimantadine for influenza (4) as well as following the introduction and widespread single-drug use of zidovudine (AZT) for HIV infection. (5) As regards the enormous importance of vaccination for prevention, on December 27, 2021, unvaccinated patients had 10 times the risk of becoming infected and 20 times the risk of death from COVID-19, compared with the fully vaccinated who had also received a booster. This implies that the risk of death from COVID-19 among patients receiving two doses and a booster is no higher than that from influenza. Moreover, the unvaccinated had 5 times the risk of becoming infected and 14 times the risk of death from COVID-19, compared to those who were vaccinated but had not received a booster. (6) In the U.S., fortunately, health care providers are the most trusted professionals by the general public, especially for reliable information about COVID-19. (7) Health care providers already have and will continue to play a crucial role in reducing preventable morbidity and mortality from COVID-19.

Today, their powerful advocacy of more widespread vaccinations is crucial to the primary prevention of COVID-19. In addition, they are now able to add to their armamentarium against COVID-19 their judicious prescription of the new antiviral drugs for high-risk, newly infected patients as soon as possible following their diagnosis, or within 5 days of the onset of symptoms. (1) In the prescription of oral antivirals, health care providers will need to inform their patients and monitor their side effects, which include renal, hepatic and adverse interactions with other widely prescribed and utilized drugs. (1) Access will be an issue for several months but it is encouraging that the U.S. Government has already bought 10 million courses of treatment from Pfizer for $5 billion. (1)

4 As of February 1, 2022, the omicron variant accounts for >99%% of all U.S. cases. Omicron was, not surprisingly, first detected in South Africa and the United Kingdom (UK), a tribute to their robust genomic surveillance of COVID-19. Notably, the U.K. leads the world in genomic surveillance, South Africa is in the top 10 whereas the U.S. is ranked 43rd. It is clear that omicron is far more transmissible but also less virulent than the delta variant. The U.S. needs to conduct far greater genomic surveillance to detect emerging variants as early as possible, especially variants which are even more resistant to the first-generation vaccines and which might be more virulent to more effectively target preventive efforts, particularly new adaptive vaccines. (8) In summary, health providers must remain cognizant that achieving much higher vaccination rates is essential to prevent, mitigate and control the U.S. epidemic and the worldwide pandemic, and to stem the continued ravaging of healthcare systems around the world. Failure to greatly reduce the incidence of active COVID-19 in the U.S. and worldwide will predictably accelerate the emergence and spread of vaccine-resistant and more virulent strains associated with greater transmissibility, giving life to the specter of global deaths from COVID-19 surpassing the number of deaths from the great influenza pandemic of 1918 --which has already occurred in the U.S --and complete devastation of healthcare systems and collapse of national economies. Health providers and political leaders must unite to urgently address "vaccine misinformation" and eliminate "vaccine hesitancy" which are fueling the current epidemic of COVID-19 in the U.S., primarily among the unvaccinated. (9)

We dedicate this manuscript to the memory of our valued mentor, colleague and dear friend, Donald B.

Louria, MD (1928 MD ( -2001 

Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19

The COVID-19 Treatment Guidelines Panel. Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19. Last Updated

Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults

Influenza antiviral drug resistance

Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase

COVID Data Tracker. Cases and deaths by vaccination status

KFF COVID-19 Vaccine Monitor

Kaiser Family Foundation

Genomic surveillance to combat COVID-19: Challenges and Opportunities

Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA